Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Olverembatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma Presents Preclinical Studies at 2025 AACR Meeting
    Ascentage Pharma Presents Preclinical Studies at 2025 AACR Meeting

    28 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/28/3069043/0/en/Ascentage-Pharma-Presents-Results-from-Five-Preclinical-Studies-at-2025-American-Association-of-Cancer-Research-AACR-Annual-Meeting-Highlighting-Strong-Synergistic-Effects-of-Olver.html

    GLOBENEWSWIRE
    28 Apr 2025
    Share Share
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/21/3064563/0/en/Ascentage-Pharma-Announces-Inclusion-of-Lisaftoclax-and-Olverembatinib-in-Chinese-Society-of-Clinical-Oncology-CSCO-2025-Guidelines.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    Ascentage Pharma Reports Full Year 2024 Financial Results
    Ascentage Pharma Reports Full Year 2024 Financial Results

    27 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/27/3050422/0/en/Ascentage-Pharma-Reports-Full-Year-2024-Unaudited-Financial-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    27 Mar 2025
    Share Share
    Olverembatinib Gets Breakthrough Status For Ph+ ALL Treatment
    Olverembatinib Gets Breakthrough Status For Ph+ ALL Treatment

    05 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/05/3037848/0/en/Olverembatinib-Granted-Breakthrough-Therapy-Designation-for-the-Treatment-of-Philadelphia-Chromosome-Positive-Ph-Acute-Lymphoblastic-Leukemia-ALL.html

    GLOBENEWSWIRE
    05 Mar 2025
    Share Share
    Olverembatinib Data Reaffirms Potential in Ponatinib Resistance
    Olverembatinib Data Reaffirms Potential in Ponatinib Resistance

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--1-5-year-follow-up-data-from-a-global-study-of-olverembatinib-reaffirms-potential-in-overcoming-resistanceintolerance-to-ponatinib-or-asciminib-302327550.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    1st Olverembatinib + Lisaftoclax Shows Potential for R/R Ph+ ALL
    1st Olverembatinib + Lisaftoclax Shows Potential for R/R Ph+ ALL

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--1st-dataset-of-olverembatinib-in-combination-with-bcl-2-inhibitor-lisaftoclax-demonstrates-potential-clinical-benefits-as-a-chemotherapy-free-regimen-for-children-with-rr-ph-all-302327474.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share